Table 2 Clinicopathological characteristics between two non-pCR group (SUVmax reduction rate (<60% or ≥60%)
Characteristic, n (%) | SUVmax reduction rate | P | |
|---|---|---|---|
< 60% | ≥ 60% | ||
n=23 | n=44 | ||
The interval days between NACRT finished and FDG-PET taken | 20 (10–46) | 20 (6–32) | 0.5705 |
Median age (range) | 65 (47–75) | 63.5 (41–75) | 0.5083 |
Gender | 0.7546 | ||
Female | 3 (13.0) | 7 (15.9) | |
Male | 20 (87.0) | 37 (84.1) | |
Tumor location | 0.8080 | ||
Upper | 5 (21.7) | 10 (22.7) | |
Middle | 10 (43.5) | 22 (50.0) | |
Lower | 8 (34.8) | 12 (27.3) | |
Tumor differentiation | 0.7346 | ||
Not poorly | 21 (91.3) | 39 (88.6) | |
Poorly | 2 (8.7) | 5 (11.4) | |
Depth of invasion (cT) | 0.7813 | ||
T1-2 | 2 (8.7) | 3 (6.8) | |
T3-4 | 21 (91.3) | 41 (93.2) | |
Lymph node metastasis (cN) | 0.8980 | ||
N1 | 15 (65.2) | 28 (63.6) | |
N2-3 | 8 (34.8) | 16 (36.4) | |
Distant metastasis (cM) | 0.0804 | ||
M0 | 19 (82.6) | 42 (95.5) | |
M1 ( Lymph node) | 4 (17.4) | 2 (4.6) | |
Clinical stage(cStage) | 0.0615 | ||
I | 2 (8.7) | 0 (0) | |
II | 0 (0) | 3 (6.8) | |
III | 17 (7.39) | 38 (86.4) | |
IVA | 0 (0) | 1 (2.3) | |
IVB | 4 (17.4) | 2 (4.6) | |
Recurrence | 0.0445a | ||
Presence | 15 (65.2) | 17 (38.6) | |
Absence | 8 (34.8) | 27 (61.4) | |
Prognosis | 0.1752 | ||
Alive | 10 (43.5) | 31 (70.5) | |
Dead with ESCC | 11 (47.8) | 10 (22.7) | |
Dead with other diseases | 2 (8.7) | 3 (6.8) | |